Currently, the value of serial SII measurements as a tool to estimate benefit for prognosis following stroke has only been investigated by Topcuoglu et al. (2021) [11], who explored the use of single measures of SII before and 24 hours after intravenous tissue plasminogen activator (tPA) treatment to predict functional outcomes and the risk of tPA-related symptomatic intracerebral hemorrhage and found the index to be only moderately sensitive and specific. The gene discussed is PLAT; the disease is Stroke.